$7.82
0.141.82%
Benzinga
Benzinga
Benzinga
금요일, 10월 16
Benzinga
© 2026 Benzinga | All Rights Reserved
Atrium Therapeutics (RNA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.77 | $-1.10 | $-1.09 | $-1.08 |
| Actual | $-1.18 | $-0.97 | $-1.59 | $-1.27 |
| Surprise | -53.3% | +11.8% | -45.9% | -17.6% |
| Revenue | ||||
| Estimate | $500000 | $2.0M | $2.0M | $2.1M |
| Actual | $3.0M | $19.6M | $860000 | $12.5M |
| Surprise | +500.8% | +881.8% | -57.0% | +498.4% |
| Metric | Q1 '27E | Q2 '27E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-1.83 | $-1.99 |
| Revenue | ||
| Consensus | — | — |
| 회계 분기 | 보고된 날짜 | 실제 EPS | 예상 EPS | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $-1.18 | $-0.77 | -53.3 % |
| Q1 | May 14, 2026 | $-0.97 | $-1.10 | 11.8 % |
| Q4 | Feb 23, 2026 | $-1.59 | $-1.09 | -45.9 % |
| Q3 | Nov 10, 2025 | $-1.27 | $-1.08 | -17.6 % |
| 회계 분기 | 보고된 날짜 | 실제 수익 | 예상 수익 | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $3.00M | $500.00K | 500.8 % |
| Q1 | May 14, 2026 | $19.64M | $2.00M | 881.8 % |
| Q4 | Feb 23, 2026 | $860.00K | $2.00M | -57.0 % |
| Q3 | Nov 10, 2025 | $12.48M | $2.08M | 498.4 % |